Is Insulet Corporation (PODD) One of the Most Oversold Healthcare Stocks to Invest In?

Insulet Corporation (NASDAQ:PODD) is one of the most oversold healthcare stocks to invest in. Insulet Corporation (NASDAQ:PODD) received a rating update from Truist on April 15. The firm cut the price target on the stock to $315 from $360 and reaffirmed a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in the MedTech sector.

Truist told investors in the research note that the firm anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around the fiscal Q1 volumes. It further stated that while the stock trades at a slight discount compared to its peer group average of high-growth profitable companies, Truist believes that it should trade at in-line levels, if not at a premium, to its peer group, given its higher revenue and profit growth prospects.

Insulet Corporation (NASDAQ:PODD) also received a rating update from RBC Capital on April 14, with the firm cutting the price target on the stock to $325 from $380 while reiterating an Outperform rating on the shares.

Insulet Corporation (NASDAQ:PODD) is a medical device company that develops, markets, and manufactures an insulin infusion system for people with insulin-dependent diabetes. The company specializes in diabetes supplies, along with other diabetes related products and supplies, including pump supplies, traditional insulin pumps, blood glucose testing supplies, and pharmaceuticals.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.